WP-1066

N/A

Report date: 2025/05/30 10:17:24
NMEFirst In Class

Base Information

Drug NameWP-1066
Drug Alias NameWP-1066
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSignal transducer and activator of transcription 3 inhibitorsMyc proto-oncogene protein inhibitorsHypoxia-inducible factor 1 alpha inhibitors
TargetsSignal transducer and activator of transcription 3Myc proto-oncogene proteinHypoxia-inducible factor 1 alpha
Therapy Area/IndicationsBrain metastasesBrain NeoplasmsMelanoma +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMoleculin Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesMoleculin Biotech IncThe University Of Texas MD Anderson Cancer CenterEmory University +[4] 
Inactive CompaniesN/A
Active IndicationsBrain metastasesBrain NeoplasmsMelanoma +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A